Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers

A Phase I Study of DN1406131 in Healthy Adults

This is a double blind Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of DN1406131, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and tryptophan 2,3-Dioxygenase 2 (TDO-2) and help the human immune system attack solid tumor cells more effectively.

Inclusion Criteria:

• Age greater of 18 years and less than 45
• Weight ≥50 kg,body mass index of 19~26 kg/m2
• Signed ICF

Exclusion Criteria:

• active autoimmune disease
• uncontrolled concurrent illness
• Smoking
• Drugs
• positive serology for HIV, Hepatitis B or C,Syphilis
• Pregnancy or breastfeeding